My research interests span many fields including immunology, oncology, virology, and more. My current project involves engineering new Chimeric Antigen Receptors (CARs) in order to address the key challenges associated with CAR T cell therapy including lack of response durability, severe toxicities, and antigen heterogeneity. Our strategy, called Mutual Antibody T cell Engagers (MATEs), involves splitting the traditional CAR design into two distinct proteins (the transmembrane/intracellular signaling domains [“MATE Receptor”] and the extracellular antigen-binding domain [“MATE ScFv”]). Our design also incorporates a linking domain to allow the two MATE components to link back together into a fully functional receptor. In this way, the activity of T cells expressing the MATE receptor (“MATE T cells”) can be controlled through fine-tunable administration of the MATE ScFv thereby improving the safety of the treatment. Furthermore, this strategy installs simple flexibility within the treatment as MATE T cells can be easily directed to new or multiple targets through modulating the antigen specificity of the MATE ScFv.
2018-present: MSc, Interdisciplinary Oncology, University of British Columbia, in progress.
2013-2018: BSc Honours (Co-op), Biopharmaceutical Science (Specialization in Genomics), University of Ottawa.